ASSOCIATION OF GENETIC VARIANTS OF CARBOPLATIN AND PACLITAXEL TRANSPORTER GENES WITH ADVERSE REACTIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

• Grant number: 24/22274-0
• Support Opportunities: Scholarships in Brazil - Master
• Start date: August 01, 2025
• End date: December 31, 2026
• Field of knowledge: Health Sciences - Pharmacy
• Principal Investigator: Patricia Moriel
• Grantee: Yasmim Gabriele Matos
• Host Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

Lung cancer is one of the main neoplasms affecting the world population. Its high incidence is mainly attributed to the range of risk predictors, especially age and smoking, while high mortality is related to late diagnosis. The disease is divided into small cell carcinoma (SCLC) and non-small cell carcinoma (NSCLC), the latter corresponding to approximately 80% of cases. Its treatment includes surgery, radiotherapy and chemotherapy, which includes targeted therapies and conventional cytotoxic therapy, based on the combination of a platinum derivative and another antineoplastic agent, such as paclitaxel. Although effective, the combination still has limitations due to the occurrence of adverse drug reactions (ADRs), such as myelosuppression and gastrointestinal reactions. Knowing that ADRs can be the result of genetic alterations, the objective of this study is to correlate genetic variants in transporter genes with the development of adverse reactions in patients with NSCLC, after the first cycle of chemotherapy, in addition to evaluating the ancestry of the participants. Participants of both sexes diagnosed with NSCLC who received antineoplastic treatment with carboplatin and paclitaxel will be included. To determine the variants, genomic DNA samples will be obtained from peripheral blood and identified through Microarray (Infinium Global Diversity Array with Enhanced PGx - GDA PGx). Myelosuppression, renal, hepatic and gastrointestinal reactions will be investigated, classified according to the Common Toxicity Criteria (CTCAE). Hardy-Weinberg equilibrium will be assessed by the Chi-square test. The comparison of allele frequencies will be assessed by Fisher's exact test and the level of significance adopted in all analyses will be 5% (p<0.05). (AU)